| 新型表皮生长因子受体抑制剂--西妥昔单抗 |
| |
| 引用本文： | 邵仲英,封宇飞,傅得兴. 新型表皮生长因子受体抑制剂--西妥昔单抗[J]. 中国全科医学, 2006, 9(4): 317-318 |
| |
| 作者姓名： | 邵仲英 封宇飞 傅得兴 |
| |
| 作者单位： | 100730,北京市,卫生部北京医院药学部 |
| |
| 摘 要： | 西妥昔单抗是一种嵌合的单克隆抗体,它选择性地与表皮生长因子受体〔存在于正常细胞(皮肤和毛发细胞)和许多肿瘤细胞(如结肠癌、直肠癌)的表面〕特异性地结合,从而抑制肿瘤细胞的增殖,诱导肿瘤细胞凋亡。本文综述了西妥昔单抗的药理作用及临床评价。
|
| 关 键 词： | 西妥昔单抗 受体 表皮生长因子 药理作用 临床评价 |
| 文章编号： | 1007-9572（2006）04-0317-02 |
| 收稿时间： | 2005-11-10 |
| 修稿时间： | 2005-11-10 |
A New Epidermal Growth Factor Receptor Inhibitor-Cetuximab |
| |
| SHAO Zhong-ying,FENG Yu-fei,FU De-xing. A New Epidermal Growth Factor Receptor Inhibitor-Cetuximab[J]. Chinese General Practice, 2006, 9(4): 317-318 |
| |
| Authors: | SHAO Zhong-ying FENG Yu-fei FU De-xing |
| |
| Abstract: | Cetuximab is a chimeric monoclonal antibody highly selective to bind the epidermal growth factor receptor(EGFR),which is found on the surface of normal cells(such skin and hair cells) and some types of cancer cells including colorectal cancer.Thus,the proliferation of the tumor cells are inhibited and apoptosis of tumor cells by inducing.The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper. |
| |
| Keywords: | Cetuximab Receptor epidermal growth factor(EGFR) Pharmacological actions Clinic evaluation |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
